[Cost effectiveness analysis of highly active antiretroviral therapy in HIV asymptomatic patients].
BACKGROUND
Assessment of cost and effectiveness in highly active antiretroviral therapy (HAART) in HIV asymptomatic patients.


METHODS
A cohort of several asymptomatic HIV-infected patients were observed under real practice and treated with two nucleosid analogues (AN) of which therapy was modified. A protease inhibitor (PI) was added and at least one AN was changed (or not), following the current clinical recommendations (1997). Data on direct cost (drug cost, visits and clinical procedures) were then recorded both three and six months after the beginning of the study. Data on effectiveness (percentage of patients with undetectable levels of viral load) and quality of life were next measured according to the EuroQol, and recorded at the same time. All patients used a monthly diary to keep record of resource consumption and quality of life progress.


RESULTS
All treatment regimens were effective in lowering the viral load and improve quality of life. The less expensive HAART was AZT + 3TC + IND (1,037,757 pesetas) and AZT + ddl + IND (1,045,339 pesetas), but both were the least effective to reduce patient's viral load to undetectable levels (52.7 and 57.7% respectively); meanwhile d4T + 3TC + IND (1,188,177 pesetas) and d4T + ddl + IND (1,212,285 pesetas) were more expensive but more effective (67.9 and 66% respectively). Cost-effectiveness ratios ranged between 9,896 and 13,122 pesetas. There was no statistically significant differences in quality of life among the different HAART regimens.


CONCLUSIONS
HAART implementation is effective in reducing patients' viral load to undetectable levels and to slightly improve their quality of life after six months. Costs and effectiveness vary according to the type of HAART treatment used.
Pinto
J L
JL
Universitat Pompeu Fabra, Barcelona. jose.pinto@econ.upf.es
López Lavid
C
C
Badia
X
X
Coma
A
A
Benavides
A
A
D000328:Adult; D019380:Anti-HIV Agents / Q000191:economics* / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D016049:Didanosine / Q000191:economics / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006679:HIV Seropositivity / Q000188:drug therapy* / Q000191:economics*; D006801:Humans; D019469:Indinavir / Q000191:economics / Q000627:therapeutic use; D019259:Lamivudine / Q000191:economics / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D019829:Nevirapine / Q000191:economics / Q000627:therapeutic use; D018434:Sickness Impact Profile; D013030:Spain; D018119:Stavudine / Q000191:economics / Q000627:therapeutic use; D019562:Viral Load; D015215:Zidovudine / Q000191:economics / Q000627:therapeutic use
D019380:Anti-HIV Agents; D019259:Lamivudine; D015215:Zidovudine; D019469:Indinavir; D019829:Nevirapine; D018119:Stavudine; D016049:Didanosine